Abstract
Introduction Digital immunoassays are generally regarded as superior tests for the detection of infectious disease pathogens, but there have been insufficient data concerning SARS-CoV-2 immunoassays.
Methods We prospectively evaluated a novel digital immunoassay (RapidTesta SARS-CoV-2). Two nasopharyngeal samples were simultaneously collected for antigen tests and RT-PCR. Real-time RT-PCR for SARS-CoV-2, using a method developed by the National Institute of Infectious Diseases, Japan, served as the reference RT-PCR method.
Results During the study period, 1,127 nasopharyngeal samples (symptomatic patients: 802, asymptomatic patients: 325) were evaluated. For digital immunoassay antigen tests, the sensitivity was 78.3% (95% CI: 67.3%–87.1%) and the specificity was 97.6% (95% CI: 96.5%–98.5%). When technicians visually analyzed the antigen test results, the sensitivity was 71.6% (95% CI: 59.9%–81.5%) and the specificity was 99.2% (95% CI: 98.5%–99.7%). Among symptomatic patients, the sensitivity was 89.4% (95% CI; 76.9%–96.5%) with digital immunoassay antigen tests, and 85.1% (95% CI; 71.7%–93.8%) with visually analyzed the antigen test, respectively.
Conclusions The findings indicated that RapidTesta SARS-CoV-2 analysis with the DIA device had sufficient analytical performance for the detection of SARS-CoV-2 in nasopharyngeal samples. When positive DIA results are recorded without a visually recognizable red line at the positive line location on the test cassette, additional RT-PCR evaluation should be performed.
Competing Interest Statement
Sekisui Medical Co., Ltd. provided fees for research expenses and provided the RapidTesta SARS-CoV-2 without charge. Yuta Maehara, Yasushi Ochiai, and Shinya Okuyama belong to Sekisui Medical Co., Ltd., the developer of the RapidTesta SARS-CoV-2.
Funding Statement
Sekisui Medical Co., Ltd. provided fees for research expenses and provided the RapidTesta SARS-CoV-2 without charge. Yuta Maehara, Yasushi Ochiai, and Shinya Okuyama belong to Sekisui Medical Co., Ltd., the developer of the RapidTesta SARS-CoV-2.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee of TMCH approved the present study (approval number: 2021-021).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
E-mail addresses of each author: Hiromichi Suzuki, hsuzuki{at}md.tsukuba.ac.jp; Yusaku Akashi, yusaku-akashi{at}umin.ac.jp; Atsuo Ueda, atsuo.ueda06090727{at}outlook.jp; Yoshihiko Kiyasu, kiyasu-tuk{at}umin.ac.jp; Yuto Takeuchi, yuto-takeuchi{at}umin.ac.jp; Yuta Maehara, yuta.maehara{at}sekisui.com; Yasushi Ochiai, yasushi-ochiai{at}sekisui.com; Shinya Okuyama, shinya.okuyama{at}sekisui.com; Shigeyuki Notake, notake{at}tmch.or.jp; Koji Nakamura, koji-nakamura{at}tmch.or.jp; Hiroichi Ishikawa, hishikawa{at}tmch.or.jp
Authorship statement. All authors meet the ICMJE authorship criteria.
Data Availability
The data are not publicly available due to their containing information that could compromise the privacy of research participants.